RN Mobile Menu

Search form


Rheumatology Network

Cold fingers? Is it primary or secondary Raynaud’s?

Raynaud’s phenomenon affects up to 5% of the general population, but for 37% of patients, it leads to connective tissue disease. In this slideshow, we compare primary and secondary Raynaud’s.  (Raynaud’s phenomenon, ©Twinschoice/Shutterstock.com)

Recent Content


Biologic anti-inflammatory agents can lead to a drop in coronary artery disease in psoriasis patients, a study shows.

Pyoderma gangrenosum (©UBMMedicaLLC). Photo by Irina Litvin, D.O

Photo Clinic: A case of pyoderma gangrenosum that failed antibiotics, steroids, other immunosuppressive agents, thalidomide and cyclosporine.

Pyoderma gangrenosum (©UBMMedicaLLC). Photo by Irina Litvin, D.O.

Case Study: A female patient presents with a case of pyoderma gangrenosum that fails multiple standard treatments.


In this slideshow, we highlight some of the upcoming studies due to be presented at the American College of Rheumatology 2016 annual meeting which begins Nov. 11 in Washington, D.C.


PsA patients show sustained improvement at two years with secukinumab, clinical trial shows.

Lymphocyte. Immune cell. (©Toey/Shutterstock.com)

Innate lymphocytes may have a role as disease targets in rheumatoid arthritis, psoriatic arthritis and/or inflammatory bowel disease, researchers say.

(Drug development ©BrigidSturgeonShutterstock.com)

In this article, we discuss the possibility of innate lymphocytes as therapeutic targets in rheumatic disease as described in Nature Reviews Rheumatology.

By clicking Accept, you agree to become a member of the UBM Medica Community.